DelMar Pharmaceuticals Inc  

(Public, NASDAQ:DMPI)   Watch this stock  
Find more results for Jeffrey Garner
7.35
-0.73 (-9.03%)
After Hours: 7.26 -0.09 (-1.22%)
Jul 26, 4:02PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.74 - 8.01
52 week 1.72 - 10.87
Open 8.01
Vol / Avg. 0.00/37,576.00
Mkt cap 81.31M
P/E     -
Div/yield     -
EPS -0.53
Shares 10.06M
Beta 0.86
Inst. own 0%
Sep 2, 2016
Q4 2016 DelMar Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 19, 2016
Q3 2016 DelMar Pharmaceuticals Inc Earnings Call
May 19, 2016
Q3 2016 DelMar Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -273.91% -114.73%
Return on average equity - -
Employees 4 -
CDP Score - -

Address

999 Broadway W Suite 720
VANCOUVER, BC V5Z 1K5
Canada
+1-604-6295989 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. Its drug candidate, VAL-083, is used in the United States as a treatment for glioblastoma multiforme (GBM). In addition to its clinical development activities in the United States, the Company has obtained certain exclusive commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its VAL-083 is granted orphan drug status by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The Company's product,VAL-083, represents a small molecule chemotherapeutic, which means that the molecular structure of VAL-083 is not an analogue or derivative of other small molecule chemotherapeutics approved for the treatment of cancer.

Officers and directors

Jeffrey A. Bacha President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Scott Praill Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Dennis M. Brown Ph.D. Chief Scientific Officer, Director
Age: 66
Bio & Compensation  - Reuters
William J. Garner M.D. Director
Age: 49
Bio & Compensation  - Reuters
Robert J. Toth Jr Director
Age: 51
Bio & Compensation  - Reuters
John K. Bell Independent Director
Age: 67
Bio & Compensation  - Reuters
Lynda Sarah Cranston Independent Director
Age: 67
Bio & Compensation  - Reuters
Erich Mohr Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters